Clinical pharmacology of platelet cyclooxygenase inhibition.
Explore this paper's citation graph
Summary
Whether a selective sparing of extraplatelet cyclooxygenase activity by low-dose aspirin will result in increased antithrombotic efficacy, fewer toxic reactions, or both remains to be established in prospective clinical trials.
- Type
- review
- Published
- 1985-12-01
- Cited by
- 458
- References
- 46
- OpenAlex
- https://openalex.org/W2011861566
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:1796418
Keywords
Cyclooxygenase, Aspirin, Platelet, Medicine, Pharmacology
References
- The influence of selective thromboxane synthetase inhibition with a novel imidazole derivative, UK-38,485, on prostanoid formation in man.
- Monitoring the entry of new platelets into the circulation after ingestion of aspirin.
- Improved aortocoronary bypass patency by low-dose aspirin (100 mg daily). Effects on platelet aggregation and thromboxane formation.
- Preparation of [acetyl-3H]aspirin and use in quantitating PGH synthase.
- Monoclonal antibodies against PGH synthase: an immunoradiometric assay for quantitating the enzyme.
- Aspirin as an antithrombotic medication.
- Selective inhibition of prostaglandin production in inflammatory exudates and gastric mucosa
- Cyclooxygenase inhibition, platelet function, and metabolite formation during chronic sulfinpyrazone dosing
- Acetylation of prostaglandin synthase by aspirin.
- In vitro prostaglandin synthesis by human glomeruli and papillae.
- Acetylation of prostaglandin synthetase by aspirin. Purification and properties of the acetylated protein from sheep vesicular gland.
- Differential inhibition of prostacyclin production and platelet aggregation by aspirin.
- Effects of sulindac and ibuprofen in patients with chronic glomerular disease. Evidence for the dependence of renal function on prostacyclin.
- Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease.
- Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects.
- Selective inhibition of thromboxane-related platelet function by low-dose aspirin in patients after myocardial infarction.
- Platelet aggregability, thromboxane A2 and malonaldehyde formation following administration of aspirin to man.
- Thromboxane A2 in skin-bleeding-time blood and in clotted venous blood before and after administration of acetylsalicylic acid.
- Sulphinpyrazone metabolism during long-term therapy.
- Arachidonate metabolism in vascular disorders.
Cited by
- Pathophysiological actions of thromboxane A2 and their pharmacological antagonism by thromboxane receptor blockade with GR32191.
- Biosynthesis, characterization and inhibition of leukotriene B4 in human whole blood.
- Aspirin and Platelet Adenosine Diphosphate Receptor Antagonists in Acute Coronary Syndromes and Percutaneous Coronary Intervention
- Emboli rate during and early after carotid endarterectomy after a single preoperative dose of 120 mg acetylsalicylic acid--a prospective double-blind placebo controlled randomised trial.
- Platelet count, not oxidative stress, may contribute to inadequate platelet inhibition by aspirin.
- The interaction of ibuprofen and diclofenac with aspirin in healthy volunteers
- Comparison of Three Aspirin Formulations in Human Volunteers
- Morning Sudden Cardiac Death
- The role of eicosanoids in human glomerular disease.
- Failure of Aspirin to Prevent Atherothrombosis
- Impaired Glucose Metabolism in Patients with Heart Failure
- Antithrombotic, anticoagulant, and thrombolytic agents.
- Impaired Platelet Function among Platelet Donors
- Cardiological evaluation of patients with a cerebral ischemic event: the relation between heart and brain
- Aspirin and Other COX-1 inhibitors.
- ANTIPLATELET THERAPY: Aspirin, Ticlopidine/Clopidogrel, and Anti-Integrin Agents
- Gastrointestinal bleeding and massive liver damage in neuroleptic malignant syndrome
- Current Strategies to Reduce Gastrointestinal Bleeding Risk Associated with Antiplatelet Agents
- Aspirin twice a day keeps new COX‐1 at bay
- Studies of platelet function, and effects of aspirin and clopidogrel treatment
Related papers
- SECONDARY PREVENTION OF MYOCARDIAL INFARCTION
- [Controversy on platelet-inhibiting drugs].
- Inhibition of platelet prostaglandin synthetase by oral aspirin.
- Aspirin in transient ischemic attacks and minor stroke: a meta-analysis.
- EFFECT OF ANTIPLATELET THERAPY ON EARLY GRAFT PATENCY AFTER CORONARY ARTERY BYPASS GRAFTING: VA COOPERATIVE STUDY # 207
- Reversible and irreversible inhibition of platelet cyclooxygenase and serotonin release by nonsteroidal antinflammatory drugs.
- A radioimmunoassay of thromboxane B2 with thromboxane B2-125I-tyramide and its application to the study on the thromboxane B2 formation during platelet aggregation.
- In vivo measurement of thromboxane B2 and 6-keto-prostaglandin F1 alpha in humans in response to a standardized vascular injury and the influence of aspirin.
- In vivo measurement of thromboxane B2 and 6-keto-prostaglandin F1 alpha in humans in response to a standardized vascular injury and the influence of aspirin.
- In vitro and ex vivo effects of aspirin in patients on a low-dose aspirin therapy.